| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Failure, Chronic | 126 | 2025 | 242 | 18.670 |
Why?
|
| Renal Insufficiency, Chronic | 65 | 2026 | 193 | 16.860 |
Why?
|
| Renal Dialysis | 73 | 2025 | 131 | 11.810 |
Why?
|
| Kidney Diseases | 48 | 2023 | 172 | 9.170 |
Why?
|
| Hypertension | 61 | 2025 | 835 | 6.420 |
Why?
|
| Glomerular Filtration Rate | 53 | 2026 | 147 | 4.900 |
Why?
|
| Humans | 417 | 2026 | 43102 | 4.740 |
Why?
|
| Healthcare Disparities | 26 | 2025 | 590 | 4.680 |
Why?
|
| United States | 148 | 2026 | 5205 | 4.670 |
Why?
|
| Cardiovascular Diseases | 29 | 2025 | 749 | 4.250 |
Why?
|
| Vitamin D | 19 | 2025 | 196 | 3.810 |
Why?
|
| Health Status Disparities | 25 | 2025 | 719 | 3.720 |
Why?
|
| Renal Insufficiency | 8 | 2025 | 19 | 3.620 |
Why?
|
| Health Services Accessibility | 19 | 2024 | 706 | 3.280 |
Why?
|
| Vitamin D Deficiency | 13 | 2022 | 107 | 3.130 |
Why?
|
| Middle Aged | 171 | 2026 | 12222 | 2.950 |
Why?
|
| Community-Institutional Relations | 17 | 2025 | 219 | 2.940 |
Why?
|
| Biomedical Research | 14 | 2021 | 502 | 2.940 |
Why?
|
| Minority Groups | 25 | 2025 | 690 | 2.920 |
Why?
|
| Community-Based Participatory Research | 17 | 2025 | 352 | 2.860 |
Why?
|
| Aged | 141 | 2026 | 8214 | 2.830 |
Why?
|
| Male | 217 | 2026 | 23409 | 2.770 |
Why?
|
| Diabetic Nephropathies | 16 | 2023 | 78 | 2.720 |
Why?
|
| Cooperative Behavior | 20 | 2025 | 269 | 2.700 |
Why?
|
| Kidney Transplantation | 13 | 2024 | 101 | 2.590 |
Why?
|
| Female | 206 | 2026 | 24698 | 2.560 |
Why?
|
| Risk Factors | 80 | 2025 | 3994 | 2.520 |
Why?
|
| Antihypertensive Agents | 18 | 2019 | 287 | 2.410 |
Why?
|
| Kidney | 23 | 2024 | 372 | 2.390 |
Why?
|
| Poverty | 12 | 2023 | 400 | 2.340 |
Why?
|
| Creatinine | 22 | 2024 | 102 | 2.300 |
Why?
|
| Nephrology | 12 | 2022 | 20 | 2.220 |
Why?
|
| Adult | 135 | 2025 | 13872 | 2.210 |
Why?
|
| Universities | 13 | 2022 | 559 | 2.120 |
Why?
|
| Blood Pressure | 23 | 2022 | 666 | 2.120 |
Why?
|
| Albuminuria | 15 | 2022 | 78 | 2.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 15 | 2025 | 760 | 2.070 |
Why?
|
| Diabetes Mellitus | 17 | 2026 | 539 | 1.960 |
Why?
|
| Health Services Research | 10 | 2018 | 161 | 1.690 |
Why?
|
| Cultural Diversity | 5 | 2025 | 193 | 1.680 |
Why?
|
| Medicare Part C | 2 | 2026 | 18 | 1.660 |
Why?
|
| Public Policy | 2 | 2023 | 36 | 1.620 |
Why?
|
| Mass Screening | 20 | 2013 | 541 | 1.610 |
Why?
|
| Research Design | 15 | 2025 | 385 | 1.610 |
Why?
|
| Obesity | 17 | 2022 | 1151 | 1.560 |
Why?
|
| Meditation | 2 | 2025 | 25 | 1.510 |
Why?
|
| Cohort Studies | 36 | 2025 | 1759 | 1.480 |
Why?
|
| Aged, 80 and over | 39 | 2026 | 2853 | 1.470 |
Why?
|
| Stress, Psychological | 4 | 2025 | 661 | 1.430 |
Why?
|
| Oxidative Stress | 10 | 2018 | 1003 | 1.360 |
Why?
|
| Disease Progression | 27 | 2025 | 667 | 1.360 |
Why?
|
| Nutrition Surveys | 21 | 2022 | 263 | 1.350 |
Why?
|
| Socioeconomic Factors | 18 | 2021 | 1234 | 1.310 |
Why?
|
| Vulnerable Populations | 9 | 2015 | 166 | 1.300 |
Why?
|
| Electronic Health Records | 3 | 2021 | 108 | 1.300 |
Why?
|
| Endocarditis | 2 | 2020 | 11 | 1.290 |
Why?
|
| Proportional Hazards Models | 25 | 2025 | 518 | 1.280 |
Why?
|
| Registries | 11 | 2025 | 437 | 1.260 |
Why?
|
| Chronic Disease | 29 | 2026 | 549 | 1.260 |
Why?
|
| Veterans | 7 | 2024 | 210 | 1.250 |
Why?
|
| Faculty | 4 | 2023 | 105 | 1.240 |
Why?
|
| Coronary Disease | 7 | 2016 | 123 | 1.240 |
Why?
|
| Prevalence | 30 | 2024 | 1612 | 1.200 |
Why?
|
| Population Surveillance | 5 | 2018 | 246 | 1.190 |
Why?
|
| Hypertension, Renal | 8 | 2010 | 16 | 1.180 |
Why?
|
| Insurance, Health | 5 | 2016 | 145 | 1.160 |
Why?
|
| Health Promotion | 13 | 2022 | 704 | 1.140 |
Why?
|
| Prospective Payment System | 2 | 2019 | 8 | 1.100 |
Why?
|
| Los Angeles | 27 | 2025 | 394 | 1.090 |
Why?
|
| Cystatin C | 3 | 2022 | 25 | 1.090 |
Why?
|
| Treatment Outcome | 23 | 2024 | 1604 | 1.080 |
Why?
|
| Risk Assessment | 22 | 2021 | 863 | 1.080 |
Why?
|
| Community Networks | 3 | 2018 | 107 | 1.080 |
Why?
|
| Allostasis | 3 | 2022 | 25 | 1.050 |
Why?
|
| Religion | 5 | 2022 | 90 | 1.050 |
Why?
|
| Cystine | 3 | 2013 | 14 | 1.040 |
Why?
|
| Public Health | 8 | 2021 | 424 | 1.020 |
Why?
|
| Adolescent | 52 | 2023 | 6081 | 1.020 |
Why?
|
| Incidence | 21 | 2025 | 1078 | 1.020 |
Why?
|
| Disease Management | 3 | 2026 | 70 | 1.010 |
Why?
|
| Malnutrition | 4 | 2020 | 44 | 0.970 |
Why?
|
| Empathy | 2 | 2018 | 33 | 0.970 |
Why?
|
| Hyperparathyroidism, Secondary | 11 | 2025 | 14 | 0.960 |
Why?
|
| Program Evaluation | 10 | 2018 | 359 | 0.960 |
Why?
|
| Body Mass Index | 11 | 2025 | 925 | 0.960 |
Why?
|
| Acetylcysteine | 3 | 2011 | 57 | 0.960 |
Why?
|
| Waiting Lists | 4 | 2017 | 38 | 0.930 |
Why?
|
| Medicine | 3 | 2023 | 37 | 0.930 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2018 | 89 | 0.900 |
Why?
|
| Parathyroid Hormone | 19 | 2025 | 41 | 0.900 |
Why?
|
| Government Regulation | 2 | 2024 | 15 | 0.900 |
Why?
|
| Hypertrophy, Left Ventricular | 5 | 2019 | 45 | 0.900 |
Why?
|
| Medicare | 8 | 2025 | 332 | 0.890 |
Why?
|
| Research | 8 | 2020 | 181 | 0.890 |
Why?
|
| Renal Replacement Therapy | 7 | 2024 | 10 | 0.880 |
Why?
|
| Inhalation Exposure | 1 | 2024 | 44 | 0.870 |
Why?
|
| Residence Characteristics | 2 | 2019 | 363 | 0.870 |
Why?
|
| Retrospective Studies | 21 | 2025 | 2544 | 0.860 |
Why?
|
| Mentors | 4 | 2023 | 145 | 0.860 |
Why?
|
| Patient Education as Topic | 4 | 2019 | 235 | 0.860 |
Why?
|
| Lung Transplantation | 1 | 2024 | 23 | 0.850 |
Why?
|
| Heart Failure | 4 | 2022 | 302 | 0.840 |
Why?
|
| Inflammation | 15 | 2025 | 758 | 0.840 |
Why?
|
| Hypoglycemic Agents | 4 | 2021 | 184 | 0.840 |
Why?
|
| Information Dissemination | 5 | 2015 | 66 | 0.830 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 112 | 0.830 |
Why?
|
| Particulate Matter | 1 | 2024 | 83 | 0.820 |
Why?
|
| Health Facilities | 1 | 2023 | 32 | 0.820 |
Why?
|
| Air Pollution | 1 | 2024 | 87 | 0.810 |
Why?
|
| Hemodialysis, Home | 3 | 2021 | 3 | 0.810 |
Why?
|
| Stroke | 6 | 2025 | 340 | 0.800 |
Why?
|
| Health Education | 7 | 2016 | 363 | 0.800 |
Why?
|
| Program Development | 14 | 2016 | 240 | 0.790 |
Why?
|
| Hospitalization | 9 | 2023 | 485 | 0.790 |
Why?
|
| Vitamins | 5 | 2022 | 81 | 0.780 |
Why?
|
| Air Pollutants | 1 | 2024 | 130 | 0.780 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 14 | 2025 | 78 | 0.780 |
Why?
|
| Health Occupations | 4 | 2008 | 19 | 0.780 |
Why?
|
| Family Health | 4 | 2010 | 55 | 0.770 |
Why?
|
| Patient Participation | 4 | 2023 | 94 | 0.770 |
Why?
|
| Cross-Sectional Studies | 32 | 2024 | 3156 | 0.760 |
Why?
|
| Age Factors | 18 | 2017 | 1154 | 0.740 |
Why?
|
| National Institutes of Health (U.S.) | 6 | 2020 | 120 | 0.730 |
Why?
|
| Public-Private Sector Partnerships | 4 | 2010 | 17 | 0.730 |
Why?
|
| Cholecalciferol | 3 | 2022 | 20 | 0.720 |
Why?
|
| Cholesterol | 6 | 2013 | 232 | 0.710 |
Why?
|
| C-Reactive Protein | 5 | 2025 | 167 | 0.700 |
Why?
|
| Heart Diseases | 1 | 2022 | 112 | 0.690 |
Why?
|
| Young Adult | 28 | 2024 | 5080 | 0.680 |
Why?
|
| Terminal Care | 4 | 2025 | 54 | 0.680 |
Why?
|
| Calcitriol | 7 | 2015 | 32 | 0.670 |
Why?
|
| Mortality | 4 | 2022 | 175 | 0.670 |
Why?
|
| Students | 6 | 2020 | 626 | 0.670 |
Why?
|
| Prediabetic State | 4 | 2023 | 69 | 0.660 |
Why?
|
| Government Programs | 1 | 2020 | 29 | 0.660 |
Why?
|
| Medical Record Linkage | 2 | 2019 | 17 | 0.660 |
Why?
|
| Clinical Trials as Topic | 7 | 2025 | 259 | 0.640 |
Why?
|
| Proteinuria | 9 | 2024 | 56 | 0.630 |
Why?
|
| Comprehensive Health Care | 1 | 2019 | 11 | 0.630 |
Why?
|
| Nephrosclerosis | 5 | 2010 | 8 | 0.630 |
Why?
|
| Antioxidants | 4 | 2013 | 443 | 0.630 |
Why?
|
| Overweight | 3 | 2018 | 249 | 0.620 |
Why?
|
| Health Surveys | 8 | 2018 | 405 | 0.620 |
Why?
|
| Prospective Studies | 18 | 2025 | 1600 | 0.620 |
Why?
|
| Quality of Life | 10 | 2023 | 616 | 0.620 |
Why?
|
| Coronary Artery Disease | 3 | 2019 | 163 | 0.620 |
Why?
|
| Calcium | 11 | 2025 | 491 | 0.610 |
Why?
|
| Apoptosis | 4 | 2014 | 1568 | 0.610 |
Why?
|
| Delivery of Health Care | 4 | 2025 | 310 | 0.610 |
Why?
|
| Child | 17 | 2023 | 3443 | 0.600 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2010 | 91 | 0.600 |
Why?
|
| Internet | 4 | 2013 | 236 | 0.600 |
Why?
|
| Patient Selection | 8 | 2025 | 205 | 0.590 |
Why?
|
| Anemia | 6 | 2023 | 55 | 0.590 |
Why?
|
| Biostatistics | 1 | 2018 | 10 | 0.590 |
Why?
|
| Sex Factors | 14 | 2017 | 1028 | 0.580 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 83 | 0.580 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 88 | 0.570 |
Why?
|
| Odds Ratio | 9 | 2020 | 587 | 0.560 |
Why?
|
| Metformin | 4 | 2023 | 75 | 0.550 |
Why?
|
| Body Weight | 4 | 2020 | 429 | 0.550 |
Why?
|
| Health Status | 4 | 2016 | 442 | 0.550 |
Why?
|
| Spirituality | 3 | 2022 | 53 | 0.550 |
Why?
|
| Triglycerides | 5 | 2012 | 147 | 0.550 |
Why?
|
| Research Subjects | 3 | 2015 | 35 | 0.550 |
Why?
|
| Longitudinal Studies | 12 | 2024 | 1063 | 0.540 |
Why?
|
| Phosphorus | 8 | 2022 | 65 | 0.540 |
Why?
|
| Emergency Service, Hospital | 2 | 2019 | 278 | 0.540 |
Why?
|
| Quality of Health Care | 4 | 2013 | 161 | 0.540 |
Why?
|
| California | 11 | 2025 | 548 | 0.540 |
Why?
|
| Research Personnel | 5 | 2022 | 206 | 0.530 |
Why?
|
| Cost of Illness | 3 | 2015 | 98 | 0.530 |
Why?
|
| Medicaid | 2 | 2017 | 143 | 0.530 |
Why?
|
| Health Behavior | 4 | 2025 | 575 | 0.530 |
Why?
|
| Reimbursement Mechanisms | 1 | 2017 | 11 | 0.510 |
Why?
|
| Depression | 5 | 2020 | 863 | 0.510 |
Why?
|
| Education | 5 | 2020 | 60 | 0.500 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 49 | 0.490 |
Why?
|
| Lipid Metabolism | 5 | 2014 | 148 | 0.490 |
Why?
|
| Muscle, Skeletal | 4 | 2013 | 316 | 0.490 |
Why?
|
| Follow-Up Studies | 16 | 2020 | 1067 | 0.490 |
Why?
|
| Drug Therapy, Combination | 6 | 2025 | 234 | 0.480 |
Why?
|
| Kidney Function Tests | 6 | 2020 | 32 | 0.480 |
Why?
|
| Awareness | 2 | 2011 | 73 | 0.480 |
Why?
|
| Poverty Areas | 2 | 2013 | 47 | 0.470 |
Why?
|
| Databases, Factual | 10 | 2020 | 341 | 0.460 |
Why?
|
| Feeding Behavior | 4 | 2012 | 469 | 0.460 |
Why?
|
| Emigrants and Immigrants | 1 | 2017 | 158 | 0.460 |
Why?
|
| Calcifediol | 2 | 2025 | 17 | 0.460 |
Why?
|
| Aging | 3 | 2013 | 783 | 0.450 |
Why?
|
| Barbering | 2 | 2016 | 14 | 0.440 |
Why?
|
| Community Health Services | 14 | 2015 | 206 | 0.440 |
Why?
|
| Urea | 2 | 2012 | 46 | 0.440 |
Why?
|
| Community Health Nursing | 1 | 2014 | 14 | 0.440 |
Why?
|
| Fatigue | 3 | 2024 | 100 | 0.440 |
Why?
|
| Schools, Medical | 4 | 2016 | 208 | 0.440 |
Why?
|
| Myocardial Ischemia | 1 | 2015 | 83 | 0.440 |
Why?
|
| Uremia | 2 | 2012 | 3 | 0.440 |
Why?
|
| Patient Care | 3 | 2022 | 31 | 0.440 |
Why?
|
| Time Factors | 16 | 2019 | 1857 | 0.440 |
Why?
|
| Length of Stay | 4 | 2025 | 229 | 0.430 |
Why?
|
| Prognosis | 11 | 2019 | 861 | 0.430 |
Why?
|
| Comorbidity | 11 | 2021 | 737 | 0.420 |
Why?
|
| Students, Nursing | 1 | 2014 | 38 | 0.410 |
Why?
|
| Selenomethionine | 2 | 2011 | 13 | 0.410 |
Why?
|
| Diabetic Retinopathy | 2 | 2013 | 78 | 0.410 |
Why?
|
| Dietary Fats | 2 | 2011 | 117 | 0.410 |
Why?
|
| Diabetes, Gestational | 2 | 2025 | 56 | 0.400 |
Why?
|
| Dietary Supplements | 4 | 2011 | 213 | 0.400 |
Why?
|
| Calcium Channel Blockers | 5 | 2009 | 55 | 0.400 |
Why?
|
| Urban Health Services | 1 | 2013 | 44 | 0.390 |
Why?
|
| Enterocytes | 1 | 2012 | 4 | 0.390 |
Why?
|
| Sarcopenia | 1 | 2013 | 15 | 0.390 |
Why?
|
| Nephrotic Syndrome | 1 | 2013 | 11 | 0.390 |
Why?
|
| Spermine | 2 | 2010 | 67 | 0.390 |
Why?
|
| Dementia | 2 | 2025 | 160 | 0.390 |
Why?
|
| Photography | 1 | 2013 | 50 | 0.390 |
Why?
|
| Urease | 1 | 2012 | 16 | 0.390 |
Why?
|
| Diagnostic Imaging | 1 | 2013 | 53 | 0.390 |
Why?
|
| Hemodialysis Units, Hospital | 3 | 2021 | 4 | 0.380 |
Why?
|
| Puerto Rico | 3 | 2026 | 1413 | 0.380 |
Why?
|
| Heart Rate | 3 | 2018 | 266 | 0.380 |
Why?
|
| Glutathione | 2 | 2010 | 171 | 0.370 |
Why?
|
| Trust | 4 | 2021 | 167 | 0.370 |
Why?
|
| Dyslipidemias | 1 | 2013 | 48 | 0.370 |
Why?
|
| Mississippi | 6 | 2025 | 129 | 0.370 |
Why?
|
| Mesenchymal Stem Cells | 2 | 2010 | 72 | 0.370 |
Why?
|
| Health Policy | 3 | 2017 | 184 | 0.370 |
Why?
|
| Hyperlipoproteinemia Type I | 1 | 2011 | 1 | 0.360 |
Why?
|
| Lipoproteins, VLDL | 1 | 2011 | 4 | 0.360 |
Why?
|
| Receptors, Lipoprotein | 1 | 2011 | 6 | 0.360 |
Why?
|
| Mexican Americans | 3 | 2012 | 226 | 0.360 |
Why?
|
| Guidelines as Topic | 3 | 2021 | 56 | 0.360 |
Why?
|
| Immune System | 1 | 2012 | 41 | 0.360 |
Why?
|
| Cell Differentiation | 5 | 2015 | 638 | 0.360 |
Why?
|
| Health Knowledge, Attitudes, Practice | 6 | 2016 | 989 | 0.360 |
Why?
|
| Early Detection of Cancer | 1 | 2016 | 449 | 0.360 |
Why?
|
| Endothelial Cells | 2 | 2011 | 329 | 0.350 |
Why?
|
| Pilot Projects | 11 | 2025 | 760 | 0.350 |
Why?
|
| Multivariate Analysis | 10 | 2017 | 638 | 0.350 |
Why?
|
| Hyperparathyroidism | 2 | 2010 | 5 | 0.350 |
Why?
|
| Developing Countries | 3 | 2021 | 113 | 0.340 |
Why?
|
| Prostatic Neoplasms | 2 | 2021 | 1092 | 0.340 |
Why?
|
| Ethics Committees, Research | 1 | 2011 | 11 | 0.340 |
Why?
|
| Life Style | 6 | 2023 | 334 | 0.340 |
Why?
|
| Free Radical Scavengers | 1 | 2011 | 64 | 0.340 |
Why?
|
| Patient Discharge | 3 | 2022 | 128 | 0.340 |
Why?
|
| Minerals | 2 | 2010 | 53 | 0.330 |
Why?
|
| Prejudice | 2 | 2009 | 116 | 0.330 |
Why?
|
| Cultural Characteristics | 2 | 2013 | 128 | 0.330 |
Why?
|
| Interinstitutional Relations | 2 | 2008 | 51 | 0.330 |
Why?
|
| Health Personnel | 4 | 2020 | 277 | 0.330 |
Why?
|
| Fatty Liver | 1 | 2011 | 77 | 0.320 |
Why?
|
| Foundations | 8 | 2010 | 12 | 0.320 |
Why?
|
| Metaphor | 1 | 2010 | 3 | 0.320 |
Why?
|
| Leadership | 2 | 2021 | 86 | 0.320 |
Why?
|
| Practice Guidelines as Topic | 4 | 2019 | 223 | 0.320 |
Why?
|
| Educational Status | 6 | 2020 | 339 | 0.320 |
Why?
|
| Data Collection | 3 | 2008 | 210 | 0.310 |
Why?
|
| Cell Shape | 1 | 2010 | 42 | 0.310 |
Why?
|
| Infant | 7 | 2020 | 1175 | 0.310 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2018 | 375 | 0.310 |
Why?
|
| Graft Rejection | 2 | 2024 | 43 | 0.310 |
Why?
|
| Algorithms | 5 | 2017 | 509 | 0.300 |
Why?
|
| Predictive Value of Tests | 6 | 2021 | 440 | 0.300 |
Why?
|
| Anemia, Sickle Cell | 2 | 2012 | 187 | 0.300 |
Why?
|
| Telemedicine | 1 | 2013 | 234 | 0.300 |
Why?
|
| Urban Population | 6 | 2016 | 374 | 0.300 |
Why?
|
| Animals | 27 | 2015 | 16992 | 0.300 |
Why?
|
| Cardiovascular System | 1 | 2009 | 37 | 0.300 |
Why?
|
| Lipoproteins, HDL | 2 | 2013 | 48 | 0.300 |
Why?
|
| Survival Rate | 8 | 2021 | 355 | 0.290 |
Why?
|
| Social Justice | 3 | 2022 | 65 | 0.290 |
Why?
|
| Morbidity | 5 | 2017 | 97 | 0.290 |
Why?
|
| Group Processes | 1 | 2009 | 23 | 0.290 |
Why?
|
| Age Distribution | 4 | 2019 | 249 | 0.290 |
Why?
|
| Hospital Mortality | 2 | 2020 | 210 | 0.290 |
Why?
|
| Forecasting | 3 | 2015 | 136 | 0.280 |
Why?
|
| Cognitive Science | 1 | 2008 | 3 | 0.280 |
Why?
|
| Nutritional Status | 4 | 2021 | 119 | 0.280 |
Why?
|
| Cell Cycle | 1 | 2010 | 346 | 0.280 |
Why?
|
| International Agencies | 1 | 2008 | 6 | 0.280 |
Why?
|
| Signal Transduction | 6 | 2013 | 2157 | 0.280 |
Why?
|
| Health Planning | 1 | 2008 | 16 | 0.280 |
Why?
|
| Fibrosis | 1 | 2008 | 169 | 0.270 |
Why?
|
| Diabetes Complications | 5 | 2014 | 102 | 0.270 |
Why?
|
| Diffusion of Innovation | 1 | 2008 | 38 | 0.270 |
Why?
|
| Collagen | 1 | 2008 | 181 | 0.270 |
Why?
|
| Aluminum | 8 | 1989 | 39 | 0.270 |
Why?
|
| Insurance Coverage | 2 | 2008 | 110 | 0.260 |
Why?
|
| Serum Albumin | 4 | 2020 | 59 | 0.260 |
Why?
|
| Databases as Topic | 1 | 2007 | 25 | 0.260 |
Why?
|
| Health Services for the Aged | 1 | 2007 | 26 | 0.250 |
Why?
|
| Hypoglycemia | 1 | 2007 | 24 | 0.250 |
Why?
|
| Indians, North American | 3 | 2025 | 192 | 0.250 |
Why?
|
| Patient Compliance | 3 | 2004 | 233 | 0.250 |
Why?
|
| Child, Preschool | 7 | 2019 | 1546 | 0.250 |
Why?
|
| Adrenergic beta-Antagonists | 5 | 2009 | 54 | 0.240 |
Why?
|
| Cross-Cultural Comparison | 1 | 2006 | 111 | 0.240 |
Why?
|
| Minority Health | 2 | 2019 | 95 | 0.240 |
Why?
|
| Sodium | 2 | 2009 | 102 | 0.240 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 3 | 2022 | 65 | 0.240 |
Why?
|
| American Heart Association | 1 | 2025 | 24 | 0.240 |
Why?
|
| Cause of Death | 5 | 2025 | 186 | 0.240 |
Why?
|
| Population Groups | 2 | 2008 | 59 | 0.230 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2025 | 10 | 0.230 |
Why?
|
| Physician's Role | 1 | 2025 | 40 | 0.230 |
Why?
|
| Gene Expression | 1 | 2008 | 701 | 0.230 |
Why?
|
| Arteriovenous Shunt, Surgical | 2 | 2021 | 5 | 0.230 |
Why?
|
| Hyponatremia | 1 | 2005 | 6 | 0.230 |
Why?
|
| Hypernatremia | 1 | 2005 | 10 | 0.230 |
Why?
|
| Urban Health | 3 | 2016 | 101 | 0.230 |
Why?
|
| Yoga | 1 | 2025 | 33 | 0.220 |
Why?
|
| Surgical Procedures, Operative | 1 | 2025 | 33 | 0.220 |
Why?
|
| Information Services | 1 | 2004 | 13 | 0.220 |
Why?
|
| Skilled Nursing Facilities | 1 | 2005 | 20 | 0.220 |
Why?
|
| Logistic Models | 4 | 2020 | 1009 | 0.220 |
Why?
|
| Hip Fractures | 1 | 2005 | 29 | 0.220 |
Why?
|
| Pastoral Care | 1 | 2004 | 7 | 0.220 |
Why?
|
| Endemic Diseases | 1 | 2004 | 23 | 0.220 |
Why?
|
| Cell Proliferation | 2 | 2011 | 1455 | 0.220 |
Why?
|
| Academies and Institutes | 2 | 2015 | 39 | 0.210 |
Why?
|
| Clergy | 1 | 2004 | 13 | 0.210 |
Why?
|
| Attitude to Death | 1 | 2004 | 23 | 0.210 |
Why?
|
| Early Diagnosis | 8 | 2010 | 68 | 0.210 |
Why?
|
| Anesthesia, Conduction | 1 | 2024 | 3 | 0.210 |
Why?
|
| Federal Government | 1 | 2024 | 7 | 0.210 |
Why?
|
| Calcium Metabolism Disorders | 1 | 2003 | 1 | 0.210 |
Why?
|
| Acidosis | 1 | 2004 | 51 | 0.210 |
Why?
|
| Receptors, Calcitriol | 4 | 2014 | 69 | 0.210 |
Why?
|
| Women's Health | 1 | 2005 | 160 | 0.210 |
Why?
|
| Brain Ischemia | 2 | 2016 | 189 | 0.210 |
Why?
|
| Apolipoproteins | 1 | 2013 | 22 | 0.210 |
Why?
|
| Mice | 9 | 2014 | 6644 | 0.210 |
Why?
|
| Sex Distribution | 3 | 2019 | 224 | 0.200 |
Why?
|
| Severity of Illness Index | 6 | 2010 | 719 | 0.200 |
Why?
|
| Peritoneal Dialysis | 6 | 2009 | 9 | 0.200 |
Why?
|
| Adipose Tissue, Brown | 2 | 2014 | 46 | 0.200 |
Why?
|
| Extreme Heat | 1 | 2023 | 4 | 0.200 |
Why?
|
| Primary Health Care | 3 | 2012 | 380 | 0.200 |
Why?
|
| New York City | 2 | 2025 | 288 | 0.200 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2023 | 20 | 0.200 |
Why?
|
| Postoperative Complications | 1 | 2025 | 263 | 0.190 |
Why?
|
| National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 1 | 2022 | 1 | 0.190 |
Why?
|
| Blood Cell Count | 1 | 2012 | 12 | 0.190 |
Why?
|
| Monocytes | 3 | 2012 | 277 | 0.190 |
Why?
|
| Income | 3 | 2020 | 160 | 0.190 |
Why?
|
| Myocytes, Cardiac | 2 | 2015 | 183 | 0.190 |
Why?
|
| Phosphorus, Dietary | 1 | 2022 | 1 | 0.190 |
Why?
|
| Systole | 2 | 2012 | 67 | 0.190 |
Why?
|
| Laboratories | 1 | 2012 | 40 | 0.190 |
Why?
|
| Survival Analysis | 5 | 2018 | 368 | 0.190 |
Why?
|
| Organizational Objectives | 2 | 2016 | 33 | 0.190 |
Why?
|
| Disease Models, Animal | 4 | 2013 | 1596 | 0.190 |
Why?
|
| Renin-Angiotensin System | 3 | 2013 | 48 | 0.190 |
Why?
|
| Hematinics | 2 | 2012 | 9 | 0.190 |
Why?
|
| Cells, Cultured | 6 | 2014 | 1621 | 0.190 |
Why?
|
| bcl-2-Associated X Protein | 3 | 2011 | 76 | 0.180 |
Why?
|
| Diet, Protein-Restricted | 2 | 2013 | 6 | 0.180 |
Why?
|
| Myostatin | 2 | 2013 | 61 | 0.180 |
Why?
|
| Lipocalins | 1 | 2011 | 6 | 0.180 |
Why?
|
| Pica | 1 | 2001 | 4 | 0.180 |
Why?
|
| China | 2 | 2021 | 229 | 0.180 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2011 | 11 | 0.180 |
Why?
|
| Communication Barriers | 2 | 2017 | 60 | 0.180 |
Why?
|
| Muscle Development | 2 | 2012 | 51 | 0.180 |
Why?
|
| Down-Regulation | 3 | 2013 | 456 | 0.180 |
Why?
|
| Research Support as Topic | 3 | 2019 | 89 | 0.180 |
Why?
|
| Vaccines | 1 | 2022 | 65 | 0.180 |
Why?
|
| Lead Poisoning, Nervous System, Childhood | 1 | 2001 | 9 | 0.180 |
Why?
|
| Calcinosis | 3 | 2008 | 62 | 0.170 |
Why?
|
| Follistatin | 2 | 2014 | 28 | 0.170 |
Why?
|
| Decision Making | 3 | 2023 | 249 | 0.170 |
Why?
|
| Rats | 11 | 2014 | 3735 | 0.170 |
Why?
|
| Blood Pressure Determination | 2 | 2016 | 54 | 0.170 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2013 | 84 | 0.170 |
Why?
|
| Developed Countries | 1 | 2021 | 16 | 0.170 |
Why?
|
| Cachexia | 2 | 2011 | 7 | 0.170 |
Why?
|
| Diuretics | 2 | 2015 | 51 | 0.170 |
Why?
|
| Risk Reduction Behavior | 2 | 2013 | 138 | 0.170 |
Why?
|
| Sex | 1 | 2001 | 4 | 0.170 |
Why?
|
| Ambulatory Care Facilities | 2 | 2013 | 68 | 0.170 |
Why?
|
| Awards and Prizes | 2 | 2018 | 28 | 0.170 |
Why?
|
| Social Conditions | 1 | 2021 | 13 | 0.170 |
Why?
|
| Uncertainty | 2 | 2021 | 32 | 0.170 |
Why?
|
| Models, Organizational | 2 | 2018 | 35 | 0.170 |
Why?
|
| Dietary Proteins | 3 | 2022 | 35 | 0.170 |
Why?
|
| Qualitative Research | 4 | 2023 | 574 | 0.170 |
Why?
|
| Cocaine-Related Disorders | 1 | 2001 | 102 | 0.170 |
Why?
|
| Double-Blind Method | 4 | 2018 | 317 | 0.160 |
Why?
|
| Circadian Rhythm | 2 | 2022 | 236 | 0.160 |
Why?
|
| Models, Cardiovascular | 1 | 2021 | 98 | 0.160 |
Why?
|
| Fractures, Bone | 1 | 2020 | 63 | 0.160 |
Why?
|
| Social Support | 3 | 2013 | 445 | 0.160 |
Why?
|
| Spleen | 1 | 2011 | 204 | 0.160 |
Why?
|
| Brazil | 3 | 2025 | 84 | 0.160 |
Why?
|
| Medically Uninsured | 2 | 2013 | 65 | 0.160 |
Why?
|
| Pain | 3 | 2001 | 290 | 0.160 |
Why?
|
| Patient Care Management | 1 | 2019 | 5 | 0.160 |
Why?
|
| North America | 1 | 2020 | 85 | 0.160 |
Why?
|
| Baltimore | 2 | 2020 | 58 | 0.160 |
Why?
|
| Walking | 1 | 2021 | 88 | 0.160 |
Why?
|
| Drug Evaluation | 2 | 1996 | 10 | 0.160 |
Why?
|
| Pain Measurement | 1 | 2001 | 183 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2011 | 152 | 0.160 |
Why?
|
| Gene Expression Profiling | 3 | 2014 | 704 | 0.160 |
Why?
|
| Single-Blind Method | 1 | 2019 | 54 | 0.160 |
Why?
|
| Hyperkalemia | 1 | 2009 | 13 | 0.150 |
Why?
|
| Faculty, Medical | 3 | 2016 | 74 | 0.150 |
Why?
|
| Pacific Islands | 1 | 2019 | 123 | 0.150 |
Why?
|
| Diabetic Foot | 1 | 2019 | 6 | 0.150 |
Why?
|
| Altitude | 1 | 2019 | 10 | 0.150 |
Why?
|
| Energy Intake | 2 | 2010 | 164 | 0.150 |
Why?
|
| Nitrogen | 2 | 2013 | 84 | 0.150 |
Why?
|
| Rats, Sprague-Dawley | 7 | 2013 | 1766 | 0.150 |
Why?
|
| Inflammation Mediators | 1 | 2020 | 140 | 0.150 |
Why?
|
| Patients | 1 | 1999 | 16 | 0.150 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 94 | 0.150 |
Why?
|
| Focus Groups | 5 | 2017 | 423 | 0.150 |
Why?
|
| Atherosclerosis | 2 | 2011 | 169 | 0.150 |
Why?
|
| Academic Medical Centers | 2 | 2016 | 76 | 0.150 |
Why?
|
| Bone Diseases | 4 | 1987 | 18 | 0.150 |
Why?
|
| Spiritual Therapies | 1 | 2018 | 8 | 0.150 |
Why?
|
| New Orleans | 1 | 2018 | 17 | 0.140 |
Why?
|
| Behavioral Research | 1 | 2019 | 41 | 0.140 |
Why?
|
| Echocardiography | 1 | 2019 | 167 | 0.140 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2018 | 4 | 0.140 |
Why?
|
| Self Care | 3 | 2005 | 175 | 0.140 |
Why?
|
| Suicide | 1 | 2020 | 140 | 0.140 |
Why?
|
| Cocaine | 1 | 2001 | 251 | 0.140 |
Why?
|
| Deferoxamine | 5 | 1988 | 17 | 0.140 |
Why?
|
| Annual Reports as Topic | 1 | 2018 | 1 | 0.140 |
Why?
|
| Nursing Homes | 1 | 2019 | 64 | 0.140 |
Why?
|
| Attitude to Health | 1 | 2001 | 338 | 0.140 |
Why?
|
| Blood Glucose | 2 | 2016 | 389 | 0.140 |
Why?
|
| HIV Infections | 2 | 2013 | 2586 | 0.140 |
Why?
|
| Nurses | 2 | 2021 | 55 | 0.130 |
Why?
|
| Health Literacy | 2 | 2024 | 130 | 0.130 |
Why?
|
| Waist Circumference | 2 | 2021 | 90 | 0.130 |
Why?
|
| Gene Expression Regulation | 4 | 2011 | 1070 | 0.130 |
Why?
|
| Ramipril | 3 | 2008 | 4 | 0.130 |
Why?
|
| Social Class | 2 | 2012 | 291 | 0.130 |
Why?
|
| Community Health Centers | 2 | 2016 | 57 | 0.130 |
Why?
|
| Patient Preference | 1 | 2017 | 60 | 0.130 |
Why?
|
| Blotting, Western | 4 | 2013 | 883 | 0.130 |
Why?
|
| Models, Theoretical | 2 | 2009 | 232 | 0.130 |
Why?
|
| Neutrophils | 2 | 2012 | 145 | 0.130 |
Why?
|
| Ketosis | 1 | 2016 | 2 | 0.130 |
Why?
|
| Behavior Therapy | 2 | 2013 | 180 | 0.130 |
Why?
|
| Hypophosphatemia | 1 | 1996 | 2 | 0.130 |
Why?
|
| Thyrotoxicosis | 1 | 1996 | 3 | 0.130 |
Why?
|
| Paralysis | 1 | 1996 | 5 | 0.130 |
Why?
|
| Congresses as Topic | 2 | 2014 | 50 | 0.130 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 2 | 2007 | 7 | 0.130 |
Why?
|
| Hypokalemia | 1 | 1996 | 11 | 0.130 |
Why?
|
| Fluid Therapy | 1 | 2016 | 29 | 0.120 |
Why?
|
| Periodicity | 1 | 1996 | 34 | 0.120 |
Why?
|
| Physicians, Women | 1 | 2016 | 4 | 0.120 |
Why?
|
| Liver | 3 | 2012 | 511 | 0.120 |
Why?
|
| Insulin Resistance | 1 | 2018 | 201 | 0.120 |
Why?
|
| Amlodipine | 2 | 2009 | 20 | 0.120 |
Why?
|
| Arteriovenous Fistula | 1 | 2016 | 12 | 0.120 |
Why?
|
| Career Mobility | 1 | 2016 | 29 | 0.120 |
Why?
|
| Dietetics | 1 | 2016 | 23 | 0.120 |
Why?
|
| Environment Design | 1 | 2016 | 32 | 0.120 |
Why?
|
| Authorship | 1 | 2015 | 6 | 0.120 |
Why?
|
| Psychometrics | 2 | 2020 | 358 | 0.120 |
Why?
|
| Energy Metabolism | 2 | 2014 | 187 | 0.120 |
Why?
|
| Maternal Health Services | 3 | 2010 | 23 | 0.120 |
Why?
|
| Peer Review, Research | 1 | 2015 | 15 | 0.120 |
Why?
|
| Public Opinion | 1 | 2015 | 20 | 0.120 |
Why?
|
| Education, Professional | 1 | 2015 | 9 | 0.120 |
Why?
|
| Motivation | 3 | 2021 | 513 | 0.120 |
Why?
|
| Writing | 1 | 2015 | 42 | 0.120 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 2 | 2022 | 23 | 0.110 |
Why?
|
| History, 20th Century | 1 | 2015 | 121 | 0.110 |
Why?
|
| Patient Care Team | 2 | 2013 | 60 | 0.110 |
Why?
|
| Pregnancy | 4 | 2025 | 1772 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2014 | 310 | 0.110 |
Why?
|
| Language | 1 | 2017 | 185 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2013 | 863 | 0.110 |
Why?
|
| Societies, Nursing | 1 | 2014 | 1 | 0.110 |
Why?
|
| England | 1 | 2014 | 11 | 0.110 |
Why?
|
| Attitude of Health Personnel | 2 | 2015 | 231 | 0.110 |
Why?
|
| Arteriovenous Anastomosis | 1 | 2014 | 2 | 0.110 |
Why?
|
| Sensitivity and Specificity | 2 | 2024 | 611 | 0.110 |
Why?
|
| Delayed-Action Preparations | 2 | 2025 | 74 | 0.110 |
Why?
|
| Capacity Building | 1 | 2015 | 99 | 0.110 |
Why?
|
| Interdisciplinary Communication | 4 | 2015 | 40 | 0.110 |
Why?
|
| Mice, Knockout | 3 | 2014 | 1035 | 0.110 |
Why?
|
| Perception | 2 | 2025 | 215 | 0.110 |
Why?
|
| Cartoons as Topic | 1 | 2014 | 3 | 0.110 |
Why?
|
| Cytokines | 1 | 2018 | 678 | 0.110 |
Why?
|
| Abnormalities, Multiple | 2 | 2008 | 38 | 0.110 |
Why?
|
| Ergocalciferols | 3 | 2010 | 6 | 0.110 |
Why?
|
| Chromosome Deletion | 2 | 2008 | 53 | 0.110 |
Why?
|
| Heart | 1 | 2015 | 184 | 0.110 |
Why?
|
| Patient Admission | 1 | 2014 | 50 | 0.100 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 3 | 1990 | 3 | 0.100 |
Why?
|
| Altruism | 1 | 2013 | 12 | 0.100 |
Why?
|
| Analysis of Variance | 3 | 2023 | 575 | 0.100 |
Why?
|
| Health Facility Size | 1 | 2013 | 5 | 0.100 |
Why?
|
| Fibroblast Growth Factors | 2 | 2025 | 36 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 652 | 0.100 |
Why?
|
| Risk | 3 | 2011 | 287 | 0.100 |
Why?
|
| Demography | 2 | 2013 | 195 | 0.100 |
Why?
|
| Radiology Information Systems | 1 | 2013 | 5 | 0.100 |
Why?
|
| Homeostasis | 3 | 2004 | 192 | 0.100 |
Why?
|
| Adipocytes | 1 | 2014 | 60 | 0.100 |
Why?
|
| Substance-Related Disorders | 1 | 2001 | 830 | 0.100 |
Why?
|
| Bone Morphogenetic Protein 7 | 2 | 2013 | 6 | 0.100 |
Why?
|
| Nursing Staff, Hospital | 1 | 2013 | 21 | 0.100 |
Why?
|
| Adipose Tissue | 2 | 2011 | 182 | 0.100 |
Why?
|
| Lipoproteins, IDL | 1 | 2013 | 1 | 0.100 |
Why?
|
| Nephritis, Interstitial | 1 | 2013 | 7 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2022 | 497 | 0.100 |
Why?
|
| Exercise | 3 | 2025 | 692 | 0.100 |
Why?
|
| Montana | 2 | 2004 | 6 | 0.100 |
Why?
|
| Case Management | 1 | 2013 | 24 | 0.100 |
Why?
|
| Database Management Systems | 1 | 2013 | 19 | 0.100 |
Why?
|
| Electric Impedance | 1 | 2012 | 28 | 0.100 |
Why?
|
| Nutrition Disorders | 1 | 2012 | 12 | 0.100 |
Why?
|
| Data Mining | 1 | 2013 | 30 | 0.100 |
Why?
|
| Tight Junctions | 1 | 2012 | 27 | 0.100 |
Why?
|
| Natural Language Processing | 1 | 2013 | 21 | 0.100 |
Why?
|
| Spheroids, Cellular | 1 | 2013 | 37 | 0.100 |
Why?
|
| Delayed Graft Function | 1 | 2012 | 2 | 0.100 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2013 | 68 | 0.100 |
Why?
|
| Lipoproteins, LDL | 1 | 2013 | 67 | 0.090 |
Why?
|
| Ethanol | 2 | 2020 | 224 | 0.090 |
Why?
|
| User-Computer Interface | 1 | 2013 | 74 | 0.090 |
Why?
|
| School Nursing | 1 | 2012 | 12 | 0.090 |
Why?
|
| Mammary Glands, Human | 1 | 2013 | 40 | 0.090 |
Why?
|
| Cultural Competency | 1 | 2013 | 138 | 0.090 |
Why?
|
| NF-kappa B | 3 | 2013 | 358 | 0.090 |
Why?
|
| Nutritive Value | 1 | 2012 | 37 | 0.090 |
Why?
|
| Macrophages | 3 | 2012 | 529 | 0.090 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2012 | 70 | 0.090 |
Why?
|
| Advance Care Planning | 2 | 2025 | 20 | 0.090 |
Why?
|
| Glucaric Acid | 1 | 2011 | 1 | 0.090 |
Why?
|
| Weight Loss | 2 | 2023 | 137 | 0.090 |
Why?
|
| Neovascularization, Physiologic | 1 | 2012 | 80 | 0.090 |
Why?
|
| Consensus | 3 | 2021 | 48 | 0.090 |
Why?
|
| Thrombocytosis | 1 | 2011 | 5 | 0.090 |
Why?
|
| Platelet Count | 1 | 2011 | 13 | 0.090 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2013 | 92 | 0.090 |
Why?
|
| Fatty Acids | 1 | 2012 | 134 | 0.090 |
Why?
|
| Cyclooxygenase 2 | 2 | 2013 | 107 | 0.090 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2012 | 388 | 0.090 |
Why?
|
| T-Lymphocytes | 2 | 2012 | 386 | 0.090 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2010 | 41 | 0.090 |
Why?
|
| School Health Services | 1 | 2012 | 90 | 0.090 |
Why?
|
| Lipogenesis | 1 | 2011 | 19 | 0.090 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2011 | 32 | 0.090 |
Why?
|
| Ferric Compounds | 1 | 2011 | 62 | 0.090 |
Why?
|
| Metoprolol | 2 | 2009 | 3 | 0.090 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2012 | 65 | 0.090 |
Why?
|
| Organizational Case Studies | 2 | 2008 | 31 | 0.080 |
Why?
|
| Dendritic Cells | 1 | 2012 | 132 | 0.080 |
Why?
|
| Self Efficacy | 1 | 2012 | 215 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 2 | 2014 | 1869 | 0.080 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 105 | 0.080 |
Why?
|
| Hypocalcemia | 1 | 2010 | 4 | 0.080 |
Why?
|
| Bone Density | 2 | 2008 | 103 | 0.080 |
Why?
|
| Hypercalcemia | 1 | 2010 | 13 | 0.080 |
Why?
|
| Hepatocytes | 1 | 2011 | 80 | 0.080 |
Why?
|
| B-Lymphocytes | 1 | 2012 | 189 | 0.080 |
Why?
|
| Bisexuality | 1 | 2013 | 211 | 0.080 |
Why?
|
| Lipoproteins | 1 | 2011 | 70 | 0.080 |
Why?
|
| Intracellular Space | 1 | 2010 | 37 | 0.080 |
Why?
|
| Hypercholesterolemia | 2 | 2009 | 42 | 0.080 |
Why?
|
| Apolipoproteins E | 1 | 2011 | 138 | 0.080 |
Why?
|
| Genes, cdc | 1 | 2010 | 8 | 0.080 |
Why?
|
| Osteomalacia | 3 | 1987 | 3 | 0.080 |
Why?
|
| Multipotent Stem Cells | 1 | 2010 | 16 | 0.080 |
Why?
|
| Aldehydes | 1 | 2010 | 70 | 0.080 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2013 | 307 | 0.080 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2010 | 138 | 0.080 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2009 | 20 | 0.080 |
Why?
|
| Social Change | 1 | 2010 | 19 | 0.080 |
Why?
|
| Endothelium, Vascular | 1 | 2011 | 263 | 0.080 |
Why?
|
| GTP Phosphohydrolases | 1 | 2010 | 34 | 0.080 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2010 | 34 | 0.080 |
Why?
|
| Motor Activity | 1 | 2012 | 437 | 0.080 |
Why?
|
| Rural Population | 1 | 2013 | 373 | 0.080 |
Why?
|
| Receptor, Melanocortin, Type 3 | 1 | 2009 | 6 | 0.080 |
Why?
|
| gamma-MSH | 1 | 2009 | 4 | 0.080 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2010 | 128 | 0.080 |
Why?
|
| Blood Platelets | 1 | 1990 | 81 | 0.080 |
Why?
|
| Models, Educational | 1 | 2009 | 46 | 0.080 |
Why?
|
| Intestinal Absorption | 3 | 2003 | 22 | 0.080 |
Why?
|
| Health Care Reform | 1 | 2009 | 36 | 0.080 |
Why?
|
| Ownership | 1 | 2009 | 12 | 0.080 |
Why?
|
| G-Protein-Coupled Receptor Kinase 4 | 1 | 2009 | 1 | 0.070 |
Why?
|
| Statistics as Topic | 2 | 2013 | 123 | 0.070 |
Why?
|
| Nutrition Policy | 1 | 2009 | 64 | 0.070 |
Why?
|
| Infant, Newborn | 3 | 2016 | 972 | 0.070 |
Why?
|
| Hemoglobins | 3 | 2019 | 113 | 0.070 |
Why?
|
| Matrix Metalloproteinase 8 | 1 | 2008 | 5 | 0.070 |
Why?
|
| Catheterization | 2 | 1995 | 22 | 0.070 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2010 | 140 | 0.070 |
Why?
|
| Enzyme Activation | 1 | 2010 | 462 | 0.070 |
Why?
|
| Human Experimentation | 2 | 2008 | 11 | 0.070 |
Why?
|
| Mice, Inbred C3H | 1 | 2008 | 80 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2008 | 8 | 0.070 |
Why?
|
| Chromosome Breakage | 1 | 2008 | 14 | 0.070 |
Why?
|
| Serpins | 1 | 2008 | 27 | 0.070 |
Why?
|
| Biopsy | 3 | 1996 | 177 | 0.070 |
Why?
|
| Nerve Growth Factors | 1 | 2008 | 34 | 0.070 |
Why?
|
| Asthma | 1 | 2013 | 416 | 0.070 |
Why?
|
| Cell Line, Tumor | 2 | 2013 | 2676 | 0.070 |
Why?
|
| Glucose | 1 | 2010 | 244 | 0.070 |
Why?
|
| Chi-Square Distribution | 3 | 2017 | 236 | 0.070 |
Why?
|
| Eye Proteins | 1 | 2008 | 63 | 0.070 |
Why?
|
| Health Care Surveys | 2 | 2008 | 152 | 0.070 |
Why?
|
| Face | 1 | 2008 | 40 | 0.070 |
Why?
|
| Education, Medical, Continuing | 2 | 2005 | 35 | 0.070 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2008 | 97 | 0.070 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 201 | 0.070 |
Why?
|
| Infant, Low Birth Weight | 1 | 2007 | 36 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 1081 | 0.070 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2007 | 35 | 0.070 |
Why?
|
| Streptokinase | 1 | 1987 | 2 | 0.070 |
Why?
|
| Peritonitis | 1 | 1987 | 11 | 0.070 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2007 | 14 | 0.070 |
Why?
|
| Heart Conduction System | 1 | 2007 | 15 | 0.070 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2007 | 39 | 0.070 |
Why?
|
| Regression Analysis | 2 | 2013 | 490 | 0.070 |
Why?
|
| Genotype | 4 | 2013 | 800 | 0.070 |
Why?
|
| Autonomic Nervous System | 1 | 2007 | 39 | 0.070 |
Why?
|
| Drug Costs | 1 | 2007 | 35 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2017 | 734 | 0.060 |
Why?
|
| Documentation | 1 | 2007 | 18 | 0.060 |
Why?
|
| Medical Records | 1 | 2007 | 48 | 0.060 |
Why?
|
| Thrombosis | 1 | 1987 | 81 | 0.060 |
Why?
|
| Chemokine CCL2 | 1 | 2007 | 95 | 0.060 |
Why?
|
| Electrocardiography | 1 | 2007 | 185 | 0.060 |
Why?
|
| Staphylococcal Infections | 1 | 1987 | 67 | 0.060 |
Why?
|
| Reference Values | 1 | 2006 | 211 | 0.060 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2008 | 226 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2003 | 153 | 0.060 |
Why?
|
| Education, Nursing, Continuing | 2 | 2016 | 14 | 0.060 |
Why?
|
| Myocardial Infarction | 1 | 2008 | 247 | 0.060 |
Why?
|
| Palliative Care | 1 | 2025 | 61 | 0.060 |
Why?
|
| Benzothiadiazines | 1 | 2005 | 3 | 0.060 |
Why?
|
| Vasopressins | 1 | 2005 | 12 | 0.060 |
Why?
|
| Phosphates | 3 | 2002 | 54 | 0.060 |
Why?
|
| Water-Electrolyte Balance | 1 | 2005 | 18 | 0.060 |
Why?
|
| Bone Resorption | 2 | 2003 | 22 | 0.060 |
Why?
|
| Patient Advocacy | 1 | 2005 | 22 | 0.060 |
Why?
|
| Hypermedia | 1 | 2004 | 1 | 0.060 |
Why?
|
| Clinical Clerkship | 1 | 2005 | 27 | 0.060 |
Why?
|
| Computer Literacy | 1 | 2004 | 5 | 0.060 |
Why?
|
| Communication | 1 | 2007 | 210 | 0.050 |
Why?
|
| Diabetic Angiopathies | 1 | 2004 | 26 | 0.050 |
Why?
|
| Acid-Base Equilibrium | 1 | 2004 | 8 | 0.050 |
Why?
|
| Blood Proteins | 1 | 2005 | 77 | 0.050 |
Why?
|
| Osteoporosis | 1 | 2005 | 45 | 0.050 |
Why?
|
| Adaptation, Psychological | 2 | 2022 | 420 | 0.050 |
Why?
|
| ROC Curve | 1 | 2024 | 159 | 0.050 |
Why?
|
| Complementary Therapies | 1 | 2005 | 51 | 0.050 |
Why?
|
| Colorectal Surgery | 1 | 2024 | 4 | 0.050 |
Why?
|
| Calcitonin | 1 | 2003 | 5 | 0.050 |
Why?
|
| Professional-Patient Relations | 1 | 2004 | 60 | 0.050 |
Why?
|
| Medically Underserved Area | 1 | 2005 | 120 | 0.050 |
Why?
|
| Physician-Patient Relations | 2 | 2004 | 148 | 0.050 |
Why?
|
| Recovery of Function | 1 | 2024 | 107 | 0.050 |
Why?
|
| Organizations | 1 | 2023 | 8 | 0.050 |
Why?
|
| Prescriptions | 1 | 2023 | 19 | 0.050 |
Why?
|
| Embryo, Mammalian | 2 | 2014 | 157 | 0.050 |
Why?
|
| Maxillofacial Injuries | 1 | 2003 | 2 | 0.050 |
Why?
|
| Clinical Competence | 1 | 2004 | 156 | 0.050 |
Why?
|
| Problem Solving | 1 | 2023 | 38 | 0.050 |
Why?
|
| Linear Models | 2 | 2017 | 317 | 0.050 |
Why?
|
| Patient Readmission | 1 | 2025 | 122 | 0.050 |
Why?
|
| Appendectomy | 1 | 2023 | 17 | 0.050 |
Why?
|
| Diet | 2 | 2024 | 826 | 0.050 |
Why?
|
| Hematology | 1 | 2012 | 2 | 0.050 |
Why?
|
| Enalapril | 1 | 2002 | 7 | 0.050 |
Why?
|
| Wounds, Gunshot | 1 | 2003 | 30 | 0.050 |
Why?
|
| Referral and Consultation | 2 | 2015 | 142 | 0.050 |
Why?
|
| Hydroxyurea | 1 | 2012 | 34 | 0.050 |
Why?
|
| Hospitals | 1 | 2023 | 117 | 0.050 |
Why?
|
| Men | 1 | 2022 | 19 | 0.050 |
Why?
|
| Syndrome | 1 | 2022 | 73 | 0.050 |
Why?
|
| Social Identification | 1 | 2022 | 65 | 0.050 |
Why?
|
| AIDS-Associated Nephropathy | 1 | 2002 | 14 | 0.050 |
Why?
|
| Pharmacists | 1 | 2022 | 61 | 0.050 |
Why?
|
| Anticholesteremic Agents | 1 | 2002 | 25 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2012 | 124 | 0.050 |
Why?
|
| Lead | 1 | 2003 | 100 | 0.050 |
Why?
|
| Leisure Activities | 1 | 2022 | 41 | 0.040 |
Why?
|
| Muscles | 1 | 2021 | 82 | 0.040 |
Why?
|
| Micronutrients | 1 | 2022 | 45 | 0.040 |
Why?
|
| Body Composition | 2 | 2013 | 159 | 0.040 |
Why?
|
| Hypogonadism | 1 | 2001 | 23 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2002 | 238 | 0.040 |
Why?
|
| Erythrocyte Inclusions | 1 | 2011 | 1 | 0.040 |
Why?
|
| Erythrocyte Count | 1 | 2011 | 11 | 0.040 |
Why?
|
| Pulse | 1 | 2001 | 7 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2013 | 1723 | 0.040 |
Why?
|
| Africa | 1 | 2021 | 82 | 0.040 |
Why?
|
| Mobility Limitation | 1 | 2021 | 21 | 0.040 |
Why?
|
| India | 1 | 2021 | 108 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2021 | 72 | 0.040 |
Why?
|
| Causality | 1 | 2010 | 45 | 0.040 |
Why?
|
| Sleep | 1 | 2022 | 185 | 0.040 |
Why?
|
| Analgesics | 1 | 2001 | 55 | 0.040 |
Why?
|
| Social Responsibility | 1 | 2020 | 16 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2013 | 536 | 0.040 |
Why?
|
| Religion and Psychology | 1 | 2020 | 27 | 0.040 |
Why?
|
| Professional Competence | 1 | 2020 | 42 | 0.040 |
Why?
|
| Testosterone | 1 | 2001 | 211 | 0.040 |
Why?
|
| Vaccination | 1 | 2022 | 355 | 0.040 |
Why?
|
| Employment | 2 | 2011 | 86 | 0.040 |
Why?
|
| Bone and Bones | 4 | 1991 | 114 | 0.040 |
Why?
|
| Software | 1 | 2021 | 236 | 0.040 |
Why?
|
| Urinalysis | 1 | 2019 | 34 | 0.040 |
Why?
|
| Potassium | 1 | 2009 | 109 | 0.040 |
Why?
|
| Rats, Inbred Dahl | 2 | 2009 | 33 | 0.040 |
Why?
|
| Health Expenditures | 1 | 2019 | 44 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 1998 | 10 | 0.040 |
Why?
|
| Transcription Factors | 2 | 2013 | 735 | 0.030 |
Why?
|
| Osteitis Fibrosa Cystica | 2 | 1989 | 2 | 0.030 |
Why?
|
| Tracheostomy | 1 | 2017 | 4 | 0.030 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2017 | 4 | 0.030 |
Why?
|
| Gastrostomy | 1 | 2017 | 8 | 0.030 |
Why?
|
| DNA-Binding Proteins | 2 | 2013 | 561 | 0.030 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2017 | 24 | 0.030 |
Why?
|
| Heredity | 1 | 2017 | 7 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2017 | 44 | 0.030 |
Why?
|
| Schools | 1 | 2020 | 283 | 0.030 |
Why?
|
| Personal Autonomy | 1 | 2017 | 22 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2017 | 45 | 0.030 |
Why?
|
| Haplotypes | 2 | 2009 | 197 | 0.030 |
Why?
|
| Family Relations | 1 | 2017 | 46 | 0.030 |
Why?
|
| Censuses | 1 | 2017 | 28 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 59 | 0.030 |
Why?
|
| Antithyroid Agents | 1 | 1996 | 1 | 0.030 |
Why?
|
| Graves Disease | 1 | 1996 | 3 | 0.030 |
Why?
|
| Propylthiouracil | 1 | 1996 | 3 | 0.030 |
Why?
|
| Potassium Chloride | 1 | 1996 | 24 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 1996 | 53 | 0.030 |
Why?
|
| Muscular Diseases | 2 | 1986 | 22 | 0.030 |
Why?
|
| Frail Elderly | 1 | 2016 | 18 | 0.030 |
Why?
|
| Acute Disease | 1 | 1996 | 155 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2017 | 452 | 0.030 |
Why?
|
| Faculty, Dental | 1 | 2015 | 2 | 0.030 |
Why?
|
| Culture | 1 | 1997 | 172 | 0.030 |
Why?
|
| Marketing of Health Services | 1 | 2015 | 8 | 0.030 |
Why?
|
| Meningitis, Bacterial | 1 | 1995 | 11 | 0.030 |
Why?
|
| Streptococcus agalactiae | 1 | 1995 | 8 | 0.030 |
Why?
|
| Choroid | 1 | 1995 | 11 | 0.030 |
Why?
|
| Retinal Vessels | 1 | 1995 | 29 | 0.030 |
Why?
|
| Streptococcal Infections | 1 | 1995 | 37 | 0.030 |
Why?
|
| Atrial Fibrillation | 1 | 2016 | 122 | 0.030 |
Why?
|
| Karyotyping | 2 | 2008 | 45 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2008 | 58 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 1285 | 0.030 |
Why?
|
| Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone | 1 | 2014 | 6 | 0.030 |
Why?
|
| Access to Information | 1 | 2014 | 15 | 0.030 |
Why?
|
| Video Recording | 1 | 2014 | 41 | 0.030 |
Why?
|
| Chromosome Mapping | 2 | 2008 | 199 | 0.030 |
Why?
|
| Cold Temperature | 1 | 2014 | 40 | 0.030 |
Why?
|
| Thermogenesis | 1 | 2014 | 26 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2014 | 110 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2014 | 181 | 0.030 |
Why?
|
| Protein Transport | 1 | 2014 | 296 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2013 | 44 | 0.030 |
Why?
|
| Arachidonate 12-Lipoxygenase | 1 | 2013 | 3 | 0.020 |
Why?
|
| Glutamate-Cysteine Ligase | 1 | 2013 | 17 | 0.020 |
Why?
|
| Ion Channels | 1 | 2013 | 74 | 0.020 |
Why?
|
| Boston | 1 | 2013 | 32 | 0.020 |
Why?
|
| Retinoid X Receptors | 1 | 2013 | 12 | 0.020 |
Why?
|
| Heme Oxygenase-1 | 1 | 2013 | 52 | 0.020 |
Why?
|
| Adenine | 1 | 2013 | 46 | 0.020 |
Why?
|
| Diacylglycerol O-Acyltransferase | 1 | 2012 | 1 | 0.020 |
Why?
|
| Fibroblast Growth Factor 1 | 1 | 2012 | 4 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-3 | 1 | 2012 | 9 | 0.020 |
Why?
|
| Erythropoiesis | 1 | 2012 | 11 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2012 | 20 | 0.020 |
Why?
|
| Curriculum | 1 | 2015 | 318 | 0.020 |
Why?
|
| Catalase | 1 | 2013 | 110 | 0.020 |
Why?
|
| Cell Separation | 1 | 2013 | 94 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2014 | 383 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2012 | 45 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2013 | 118 | 0.020 |
Why?
|
| Pediatrics | 1 | 2013 | 70 | 0.020 |
Why?
|
| PPAR gamma | 1 | 2012 | 55 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2013 | 149 | 0.020 |
Why?
|
| Graft Survival | 1 | 2012 | 47 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2014 | 281 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2013 | 100 | 0.020 |
Why?
|
| Aorta, Thoracic | 1 | 2011 | 31 | 0.020 |
Why?
|
| Diastole | 1 | 2012 | 47 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 179 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2013 | 154 | 0.020 |
Why?
|
| Food Preferences | 1 | 2012 | 73 | 0.020 |
Why?
|
| Dialysis | 1 | 2011 | 7 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2013 | 99 | 0.020 |
Why?
|
| MyoD Protein | 1 | 2011 | 9 | 0.020 |
Why?
|
| Vasodilation | 1 | 2011 | 64 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2013 | 408 | 0.020 |
Why?
|
| Diagnosis-Related Groups | 1 | 2011 | 12 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 183 | 0.020 |
Why?
|
| Growth Differentiation Factors | 1 | 2011 | 7 | 0.020 |
Why?
|
| Albumins | 1 | 2011 | 33 | 0.020 |
Why?
|
| Erythropoietin | 1 | 2011 | 38 | 0.020 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2011 | 28 | 0.020 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2011 | 25 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2013 | 347 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2011 | 60 | 0.020 |
Why?
|
| Risk Adjustment | 1 | 2011 | 18 | 0.020 |
Why?
|
| Israel | 1 | 2010 | 21 | 0.020 |
Why?
|
| Thiobarbituric Acid Reactive Substances | 1 | 2010 | 13 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2010 | 62 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2011 | 238 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 220 | 0.020 |
Why?
|
| Bone Density Conservation Agents | 1 | 2010 | 28 | 0.020 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2012 | 300 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2010 | 57 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2010 | 75 | 0.020 |
Why?
|
| Adiponectin | 1 | 2010 | 59 | 0.020 |
Why?
|
| Carbon-Carbon Ligases | 1 | 2009 | 1 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2010 | 108 | 0.020 |
Why?
|
| Scavenger Receptors, Class E | 1 | 2009 | 5 | 0.020 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2009 | 5 | 0.020 |
Why?
|
| Sterol Regulatory Element Binding Protein 2 | 1 | 2009 | 5 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2011 | 165 | 0.020 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2009 | 12 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2010 | 105 | 0.020 |
Why?
|
| Cytosol | 1 | 1990 | 97 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2010 | 227 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2013 | 386 | 0.020 |
Why?
|
| Sucralfate | 1 | 1989 | 2 | 0.020 |
Why?
|
| Drug Prescriptions | 1 | 2010 | 60 | 0.020 |
Why?
|
| Antidepressive Agents | 1 | 2010 | 65 | 0.020 |
Why?
|
| Telemetry | 1 | 2009 | 14 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2009 | 70 | 0.020 |
Why?
|
| Sodium, Dietary | 1 | 2009 | 22 | 0.020 |
Why?
|
| Personal Satisfaction | 1 | 2010 | 76 | 0.020 |
Why?
|
| Leptin | 1 | 2010 | 118 | 0.020 |
Why?
|
| Receptors, Scavenger | 1 | 2009 | 16 | 0.020 |
Why?
|
| Nephrectomy | 1 | 2009 | 30 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2011 | 187 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2010 | 282 | 0.020 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2008 | 18 | 0.020 |
Why?
|
| Bone Diseases, Metabolic | 1 | 1988 | 14 | 0.020 |
Why?
|
| Parents | 1 | 2012 | 370 | 0.020 |
Why?
|
| Cell Line | 1 | 2012 | 1410 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2011 | 384 | 0.020 |
Why?
|
| Microcephaly | 1 | 2008 | 21 | 0.020 |
Why?
|
| Alleles | 1 | 2009 | 352 | 0.020 |
Why?
|
| Cell Survival | 1 | 2011 | 945 | 0.020 |
Why?
|
| Social Environment | 1 | 2010 | 218 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2008 | 98 | 0.020 |
Why?
|
| Renin | 1 | 2007 | 26 | 0.020 |
Why?
|
| I-kappa B Proteins | 1 | 2007 | 36 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2012 | 1271 | 0.020 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2007 | 30 | 0.020 |
Why?
|
| Developmental Disabilities | 1 | 2008 | 67 | 0.020 |
Why?
|
| Autonomic Nerve Block | 1 | 2007 | 2 | 0.020 |
Why?
|
| Atropine | 1 | 2007 | 12 | 0.020 |
Why?
|
| Propranolol | 1 | 2007 | 18 | 0.020 |
Why?
|
| Long QT Syndrome | 1 | 2007 | 15 | 0.020 |
Why?
|
| Body Size | 1 | 2007 | 49 | 0.020 |
Why?
|
| Lipids | 1 | 2009 | 256 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2007 | 104 | 0.020 |
Why?
|
| Calcium Carbonate | 1 | 1987 | 11 | 0.020 |
Why?
|
| Angiotensin II | 1 | 2007 | 102 | 0.020 |
Why?
|
| Needles | 1 | 1986 | 10 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2009 | 321 | 0.020 |
Why?
|
| Recurrence | 1 | 1987 | 152 | 0.020 |
Why?
|
| Hematologic Diseases | 1 | 1986 | 13 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 968 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2009 | 258 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2007 | 91 | 0.020 |
Why?
|
| Public Health Informatics | 1 | 2006 | 9 | 0.020 |
Why?
|
| Alkaline Phosphatase | 2 | 2000 | 54 | 0.010 |
Why?
|
| Administration, Oral | 2 | 2001 | 260 | 0.010 |
Why?
|
| Fractures, Spontaneous | 1 | 1985 | 6 | 0.010 |
Why?
|
| Injections, Intravenous | 2 | 2001 | 67 | 0.010 |
Why?
|
| DNA | 1 | 2009 | 592 | 0.010 |
Why?
|
| Phenotype | 1 | 2008 | 780 | 0.010 |
Why?
|
| Models, Biological | 1 | 2009 | 712 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2009 | 561 | 0.010 |
Why?
|
| Competency-Based Education | 1 | 2005 | 11 | 0.010 |
Why?
|
| Specialization | 1 | 2005 | 26 | 0.010 |
Why?
|
| Violence | 1 | 2006 | 136 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2007 | 986 | 0.010 |
Why?
|
| Education, Medical, Graduate | 1 | 2004 | 61 | 0.010 |
Why?
|
| Metabolic Diseases | 1 | 2004 | 40 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 1124 | 0.010 |
Why?
|
| Calcaneus | 1 | 2003 | 4 | 0.010 |
Why?
|
| Skull Fractures | 1 | 2003 | 4 | 0.010 |
Why?
|
| Facial Bones | 1 | 2003 | 6 | 0.010 |
Why?
|
| Spectrometry, X-Ray Emission | 1 | 2003 | 20 | 0.010 |
Why?
|
| Foreign Bodies | 1 | 2003 | 6 | 0.010 |
Why?
|
| Nose | 1 | 2003 | 11 | 0.010 |
Why?
|
| Pharynx | 1 | 2003 | 16 | 0.010 |
Why?
|
| Tibia | 1 | 2003 | 26 | 0.010 |
Why?
|
| Radiography | 1 | 2003 | 71 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2004 | 245 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2003 | 162 | 0.010 |
Why?
|
| Mouth | 1 | 2003 | 54 | 0.010 |
Why?
|
| Students, Medical | 1 | 2005 | 158 | 0.010 |
Why?
|
| Occupational Exposure | 1 | 2003 | 91 | 0.010 |
Why?
|
| Patient-Centered Care | 1 | 2003 | 75 | 0.010 |
Why?
|
| Needs Assessment | 1 | 2003 | 178 | 0.010 |
Why?
|
| Half-Life | 1 | 2001 | 63 | 0.010 |
Why?
|
| Drug Administration Routes | 1 | 2001 | 14 | 0.010 |
Why?
|
| Administration, Cutaneous | 1 | 2001 | 48 | 0.010 |
Why?
|
| Hormones | 1 | 2001 | 55 | 0.010 |
Why?
|
| Arteriosclerosis | 1 | 2001 | 43 | 0.010 |
Why?
|
| Environmental Exposure | 1 | 2003 | 256 | 0.010 |
Why?
|
| Carotid Artery Diseases | 1 | 2001 | 26 | 0.010 |
Why?
|
| Smoking | 1 | 2007 | 1024 | 0.010 |
Why?
|
| Biological Availability | 2 | 1990 | 116 | 0.010 |
Why?
|
| Kidney Diseases, Cystic | 1 | 1998 | 3 | 0.010 |
Why?
|
| Hand Deformities, Congenital | 1 | 1998 | 3 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 1998 | 61 | 0.010 |
Why?
|
| Craniofacial Abnormalities | 1 | 1998 | 24 | 0.010 |
Why?
|
| Radioisotope Renography | 1 | 1996 | 9 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 1996 | 61 | 0.010 |
Why?
|
| Injections, Intraventricular | 1 | 1995 | 59 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1995 | 53 | 0.010 |
Why?
|
| Hypotension | 1 | 1995 | 24 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 1995 | 87 | 0.010 |
Why?
|
| Microspheres | 1 | 1995 | 49 | 0.010 |
Why?
|
| Hemodynamics | 1 | 1995 | 100 | 0.010 |
Why?
|
| Random Allocation | 1 | 1995 | 147 | 0.010 |
Why?
|
| Swine | 1 | 1995 | 212 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 1995 | 352 | 0.010 |
Why?
|
| Parathyroid Glands | 1 | 1991 | 4 | 0.010 |
Why?
|
| Injections | 1 | 1991 | 42 | 0.010 |
Why?
|
| Magnesium | 1 | 1991 | 94 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 1989 | 13 | 0.000 |
Why?
|
| Aluminum Hydroxide | 1 | 1989 | 8 | 0.000 |
Why?
|
| Osteoblasts | 1 | 1989 | 44 | 0.000 |
Why?
|
| Brain Diseases | 1 | 1988 | 31 | 0.000 |
Why?
|
| Bone Development | 1 | 1987 | 28 | 0.000 |
Why?
|
| Brain | 1 | 1995 | 1472 | 0.000 |
Why?
|
| Injections, Intraperitoneal | 1 | 1986 | 60 | 0.000 |
Why?
|
| Gels | 1 | 1987 | 45 | 0.000 |
Why?
|
| Complement System Proteins | 1 | 1986 | 25 | 0.000 |
Why?
|
| Parenteral Nutrition, Total | 1 | 1986 | 2 | 0.000 |
Why?
|
| Microscopy, Fluorescence | 1 | 1986 | 256 | 0.000 |
Why?
|